TICKERNERD
Menu
IMAIMAHealthcare · Biotechnology

IMA Stock Forecast: ImageneBio, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$5.61
−0.09% on the day

The 4 Wall Street analysts covering ImageneBio, Inc. hold a median 12-month price target of $24 — +328.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 28 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$62.7M
Ticker Nerd rank
28 / 100
Median analyst target
$24
Analysts covering
4
Total return, dividends reinvested
1W
−4.0%
1M
−6.6%
YTD
−18.8%
1Y
−60.2%
From 52W high
−60.6%
From 52W low
+23.2%
$5
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IMA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores ImageneBio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
28 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
80
Volatility
68
Revisions
65
Quality
53
Issuance
38
Accruals
27
Growth
25
Momentum
24
Value
7

Size (80): Smaller than most of the companies we track.

Value (7): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IMA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IMA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25$30Oct 25Jan 26Apr 26Jul 26IMAHigh $28Median $24Low $2

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts
3 Buy0 Hold1 Sell
Low $2Median $24High $28

The green dot is the last close — the median target sits +328.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
21 Aug 2026HC Wainwright & Co.InitiatesBuy$28
11 May 2026WedbushReiteratesUnderperform$2.00
25 Nov 2025WedbushAssumesUnderperform$2.00
24 Oct 2025Leerink PartnersInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IMA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

IMA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

ImageneBio, Inc. (IMA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.6×

Cheaper than 80% of US stocks

Price / sales
78.3×

Cheaper than 5% of US stocks

Price / book
0.4×

Cheaper than 86% of US stocks

EV / EBITDA
1.2×

Cheaper than 57% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−6056.4%

Higher than 3% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−82.7%

Higher than 15% of US stocks

Return on assets
−43.1%

Higher than 10% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

IMA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IMAImageneBio, Inc.$62.7M
28
TENXTenax Therapeutics, Inc.$65.5M
31
HYFTMindWalk Holdings Corp.$65.8M
57
EXOZeXoZymes, Inc.$66.4M
11
BSEMBioStem Technologies, Inc.$63.1M
42
BOLDBoundless Bio, Inc.$67.2M
74
CRDFCardiff Oncology, Inc.$67.8M
42

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own ImageneBio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IMA news & analysis

ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 17 Aug 2026neutral

ImageneBio announced that on August 14, 2026, its Compensation Committee granted inducement awards to three newly hired non-executive employees, comprising 79,000 restricted stock units and 56,525 non-qualified stock options, under Nasdaq Listing Rule 5635(c)(4). The company also granted inducement awards of 65,000 RSUs and 56,000 NSOs to Chief Financial Officer Yanina Grant-Huerta, who additionally received 39,000 RSUs under the 2025 Equity Incentive Plan.

Why it matters — The inducement grants signal new executive and employee hiring and equity incentives tied to the company's 2025 equity plans, which IMA watchers may track for compensation and dilution effects.

ImageneBio Reports Second Quarter 2026 Financial Results

GlobeNewsWire · 5 Aug 2026neutral

ImageneBio reported its financial results for the second quarter ended June 30, 2026, and provided a company update highlighting its OX40-targeting candidate Olevaprubart (IMG-007).

Why it matters — The update provides the first look at the company's financial position and progress on Olevaprubart, a potential first-in-class OX40 antagonist that is ImageneBio's lead pipeline candidate.

FAQ

Frequently asked questions about IMA stock

What is the IMA stock price forecast for 2026-2027?

The 4 Wall Street analysts covering ImageneBio, Inc. have a median 12-month price target of $24, with estimates ranging from $2 to $28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IMA stock a buy right now?

Of the 4 analysts covering ImageneBio, Inc., 3 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks ImageneBio, Inc. 28 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IMA?

As at 22 Aug 2026, ImageneBio, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (80 of 100).

Will IMA stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +328.2% from the last close, and Ticker Nerd's factor model ranks ImageneBio, Inc. 28 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IMA stock forecast for 2030?

No analyst covering ImageneBio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $28 over the next 12 months.

How has IMA stock performed over the past year?

ImageneBio, Inc. returned -60.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ImageneBio, Inc. do?

ImageneBio, Inc. is a clinical-stage biotechnology company specializing in the development of therapeutics for immunological, autoimmune, and inflammatory diseases.

What is the latest news on IMA?

The most recent item we track (GlobeNewsWire, 17 Aug 2026): "ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)". ImageneBio announced that on August 14, 2026, its Compensation Committee granted inducement awards to three newly hired non-executive employees, comprising 79,000 restricted stock units and 56,525 non-qualified stock options, under Nasdaq Listing Rule 5635(c)(4). The company also granted inducement awards of 65,000 RSUs and 56,000 NSOs to Chief Financial Officer Yanina Grant-Huerta, who additionally received 39,000 RSUs under the 2025 Equity Incentive Plan.

Company

About ImageneBio, Inc.

ImageneBio, Inc. is a clinical-stage biotechnology company specializing in the development of therapeutics for immunological, autoimmune, and inflammatory diseases. The company is driven by the mission to transform patient outcomes through innovative medicines that aim to not only control symptoms but also alter the course of serious immune-related conditions. Leveraging both external innovation and its proprietary QuadraTek® platform, ImageneBio is focused on creating differentiated therapies with optimized safety, efficacy, and convenience profiles. Its lead product candidate, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that has progressed through Phase 2a clinical trials targeting atopic dermatitis and alopecia areata. The company's research and development pipeline is engineered to address a broad spectrum of immune and inflammatory indications, supporting its goal to pioneer next-generation treatments for underserved patient populations. Founded in 2016 and headquartered in San Diego, ImageneBio plays a significant role in the biotechnology sector by striving to improve quality of life for those affected by chronic immunological and inflammatory diseases.

CEO Dr. Kristin Yarema Ph.D. · 18 employees · United States · https://www.inmagenebio.com